Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations.
Corbin J EuleThomas W FlaigKaty WongRyon P GrafElaine T LamPublished in: Prostate cancer and prostatic diseases (2022)
In this small cohort of mPCA patients with tissue assessed PI3K pathway alterations, mTORi therapy was not effective with few PSA responses and short duration of therapy.